Sort   by:  
 Page size 
UnknownThe impact of viral mutations on recognition by SARS-CoV-2 specific T cells.
Not available
S-EPMC8552693 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownRetrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.
Not available
S-EPMC7505971 | biostudies-literature
UnknownIrbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.
Not available
S-EPMC6934233 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownThe genome of the kinetoplastid parasite, Leishmania major.
Not available
S-EPMC1470643 | biostudies-literature
UnknownRespiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study.
Not available
S-EPMC9469080 | biostudies-literature
UnknownGlobal COVID-19 lockdown highlights humans as both threats and custodians of the environment.
Not available
S-EPMC8135229 | biostudies-literature
UnknownA multi-country analysis of COVID-19 hospitalizations by vaccination status.
Not available
S-EPMC10935543 | biostudies-literature
UnknownSafety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Not available
S-EPMC8639161 | biostudies-literature
Sort   by:  
 Page size